Blood Group Antigen Targeting Peptide Suppresses Thrombotic Microangiopathy in Renal Glomerular Capillaries after ABO-Incompatible Blood Reperfusion

機関リポジトリ HANDLE Web Site

この論文をさがす

抄録

Background. Antibody-mediated rejection （AMR） after ABO-incompatible kidney transplantation （ABO-I KTx） is a major barrier to the success of transplantation. The advent of immunosuppressive therapy has markedly improved graft survival in ABO-I KTx. However, compare with a normal KTx, clinical conditions during ABO-IKTx are difficult to control due to over-immunosuppression. To reduce the immunosuppression we try to develop the blood group antigen-neutralizing therapy. Methods. We screened an ABO blood group antigen targeting peptide （BATP） by peptide library displayed T7 phage screening. After screening, a hemagglutination（ HA） inhibition assay and ELISA assay was used to analyze the blood group antigen blocking effect of the BATP. We also tested the inhibitory effect of anti-blood group Ab binding in normal human kidney tissues blocked with BATP. Results. We identified six peptide sequences. BATP efficiently suppresses hemagglutination of red blood cells caused by anti-ABO blood group antibodies and binding of these antibodies to ABO histo-blood group antigens on kidney tissue. Conclusions. These data indicating that blood group A/B-antigen on RBCs and on kidney tissues may neutralize by BATP. This approach may enable the development of novel blood group antigen neutralizing therapy to overcome the challenges of ABO-I KTx.

弘前医学. 64(Suppl.), 2013, p.S121-S128

収録刊行物

  • 弘前医学

    弘前医学 64 (Supplement), S121-S128, 2013-04-02

    弘前大学大学院医学研究科・弘前医学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ